TuHURA Biosciences (HURA) Capital Expenditures (2022 - 2026)
TuHURA Biosciences (HURA) posted quarterly Capital Expenditures of $48846.0 for Q1 2026, up 168.21% year-over-year from $18211.9 in Q1 2025, and up 126.32% quarter-over-quarter from -$185574.0 in Q4 2025.
TuHURA Biosciences (HURA) Capital Expenditures (2022 - 2026) Analysis & Trends
TuHURA Biosciences' Capital Expenditures history runs 5 years deep, the most recent figure standing at $48846.0 for Q1 2026.
- In Q1 2026, Capital Expenditures rose 168.21% year-over-year to $48846.0; the TTM figure through Mar 2026 stood at -$34540.0 (down 167.64% YoY), while the FY2025 annual figure was -$154998.0, down 45.38% from the prior year.
- Capital Expenditures for Q1 2026 stood at $48846.0, up from -$185574.0 in the prior quarter.
- The five-year high for Capital Expenditures was $232000.0 in Q3 2022, with the low at -$185574.0 in Q4 2025.
- The 5-year median for Capital Expenditures is $34423.0 (2023), against an average of $26852.2.
- Peak annual rise in Capital Expenditures reached 262.49% in 2025, while the deepest fall reached 226.13% in 2025.
- TuHURA Biosciences' Capital Expenditures stood at $232000.0 in 2022, then slumped by 91.38% to $20000.0 in 2023, then jumped by 666.42% to $153283.0 in 2024, then sank by 221.07% to -$185574.0 in 2025, then soared by 126.32% to $48846.0 in 2026.
- Business Quant data shows HURA's Capital Expenditures at $48846.0 in Q1 2026, -$185574.0 in Q4 2025, and -$39804.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | TuHURA Biosciences | 37.61 Mn | 37.61 Mn | - | 136,978.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48,846.00 |
| Mar 31, 2026 | 48,846.00 |
| Dec 31, 2025 | -185,574.00 |
| Dec 31, 2025 | -185,574.00 |
| Sep 30, 2025 | -39,804.00 |
| Sep 30, 2025 | -39,804.00 |
| Jun 30, 2025 | 141,992.00 |
| Jun 30, 2025 | 141,992.00 |
| Mar 31, 2025 | -71,612.00 |
| Mar 31, 2025 | -71,612.00 |
| Sep 30, 2024 | 153,283.00 |
| Sep 30, 2024 | 153,283.00 |
| Jun 30, 2024 | -87,386.00 |
| Jun 30, 2024 | -87,386.00 |
| Mar 31, 2024 | 56,777.00 |
| Mar 31, 2024 | 56,777.00 |
| Dec 31, 2023 | 20,000.00 |
| Dec 31, 2023 | 20,000.00 |
| Sep 30, 2022 | 232,000.00 |
| Sep 30, 2022 | 232,000.00 |